|
|
Blood, 1 January 2008, Vol. 111, No. 1, pp. 3.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS
Comment on Gardiner et al, page 165
Braking platelet activation: deactivating the receptors
Koneti A. Rao
SOL SHERRY THROMBOSIS RESEARCH CENTER, TEMPLE UNIVERSITY SCHOOL OF MEDICINE
Glycoprotein (GP) VI and Fc receptor Fc RIIa are 2 ITAM (immunoreceptor tyrosine-activation motif)–bearing platelet surface receptors. In this issue of Blood, Gardiner and colleagues show that activation of either receptor results in simultaneous proteolytic cleavage of GPVI ectodomain and FcRIIa cytoplasmic tail, providing distinct mechanisms for their down-regulation on platelet activation.
The interaction between the platelet and subendothelial matrix, a process mediated by platelet receptors GPVI for collagen and GPIb-IX-V for von Willebrand factor, is an initial event in thrombus formation on vessel injury. Although we know a lot about the events following receptor activation, our understanding is limited with respect to the mechanisms that down-regulate these responses once activated. Glycoprotein VI (GPVI) is a member of the immunoglobulin (Ig) receptor family with 2 extracellular Ig domains; it is noncovalently linked with an Fc receptor -chain (FcR) dimer, an association essential for GPVI surface expression. The cytoplasmic portion of FcR has an ITAM that is phosphorylated by Src family kinases on GPVI activation, culminating in the cleavage of the extracellular domain of GPVI and down-regulation of receptor function. The ITAM-dependent mechanisms are essential to this process. Also present on platelet surface is the IgG receptor FcRIIa, which has 2 extracellular Ig domains and, importantly, an ITAM in the cytoplasmic domain. Ligation of this receptor by immune complexes induces platelet activation.
Gardiner and colleagues have explored the interplay of the 2 ITAM-bearing receptors to address whether signaling through FcRIIa would also induce the cleavage of the GPVI ectodomain that was previously noted with GPVI ligation.1 They demonstrate that antibody ligation of platelet FcRIIa results in the shedding of GPVI ectodomain mediated by a metalloproteinase, as well as cleavage of FcRII intracellular domain by calpain. This parallel but differential cleavage of the 2 receptors was also observed on activation of GPVI, providing evidence of simultaneous down-regulation by distinct proteolytic cleavage of both receptors on ligation of either ITAM-bearing receptor. These observations extend our insights of the mechanisms that terminate signaling through these receptors in the context of hemostasis and thrombosis.
From the clinical perspective, there are important implications. Platelet FcRIIa mediates the intense platelet activation that accompanies heparin-induced thrombocytopenia (HIT) induced by platelet binding of the immune complexes. Gardiner et al go on to demonstrate in vitro down-regulation of GPVI and FcRIIa in platelets exposed to IgG from HIT patients. This predicts blunted collagen-induced platelet activation in HIT patients, a finding of considerable interest and in need of further supporting evidence. Also relevant in this context are the previous observations that GPVI antibody depletes platelet GPVI in vivo and decreases collagen responses in immune thrombocytopenic purpura (ITP) patients2,3 and in mouse models,4,5 and that GPVI antibody has an antithrombotic effect.5 Proteolytic cleavage of GPVI is the mechanism in at least some of these studies. Moreover, for both receptors studied by Gardiner et al, calmodulin is a major intermediary player and calmodulin inhibitors induce their cleavage, suggesting a potential role for these agents as antithrombotic strategies to down-regulate platelet receptor function, provided that their other effects on hematopoietic cells are not a limitation.
Footnotes
Conflict-of-interest disclosure: The author declares no competing financial interests. 
REFERENCES
- Berndt MC, Karunakaran D, Gardiner EE, Andrews RK. Programmed autologous cleavage of platelet receptors. J Thromb Haemost 2007; 5:Suppl 1, 212–219.[Medline]
[Order article via Infotrieve]
- Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood 1987; 69:1712–1720.[Abstract/Free Full Text]
- Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood 2004; 104:1350–1355.[Abstract/Free Full Text]
- Boylan B, Berndt MC, Kahn ML, Newman PJ. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents. Blood 2006; 108:908–914.[Abstract/Free Full Text]
- Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001; 193:459–469.[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcRIIa
- Elizabeth E. Gardiner, Denuja Karunakaran, Jane F. Arthur, Fi-Tjen Mu, Maree S. Powell, Ross I. Baker, P. Mark Hogarth, Mark L. Kahn, Robert K. Andrews, and Michael C. Berndt
Blood 2008 111: 165-174.
[Abstract]
[Full Text]
[PDF]
| |
